Form 4: Travere Therapeutics Executive Sells Shares to Cover Tax Obligations After PSU Vesting

Jula Inrig, Chief Medical Officer of Travere Therapeutics, sold shares to cover tax obligations following the vesting of performance-based restricted stock units (PSUs) due to the satisfaction of clinical/regulatory performance criteria.

Summary

• On February 10, 2025, Jula Inrig, the Chief Medical Officer of Travere Therapeutics, had 8,000 performance-based restricted stock units (PSUs) vest.
• The vesting was triggered by the satisfaction of certain clinical/regulatory performance criteria, including confirming a path forward for submitting an sNDA for traditional approval of FILSPARI (sparsentan) in FSGS.
• Following the vesting, Inrig sold 2,568 shares on February 12, 2025, at a price of $23.5302 per share.
• This sale was mandated by Travere Therapeutics to cover the tax withholding obligation associated with the settlement of the vested PSUs.
• After the transactions, Inrig directly owns 89,602 shares of Travere Therapeutics common stock.

Sentiment

Score: 7

Explanation: The document indicates positive progress in meeting clinical/regulatory milestones, as evidenced by the PSU vesting. The stock sale is a routine transaction for tax purposes and doesn't necessarily reflect a negative sentiment.

Positives

• The vesting of the PSUs indicates that Travere Therapeutics has met certain clinical/regulatory performance criteria.
• Confirmation of a path forward for submitting an sNDA for traditional approval of FILSPARI (sparsentan) in FSGS is a positive development.

Future Outlook

The document does not contain specific forward-looking statements beyond the implication that the company is progressing towards sNDA submission for FILSPARI.

Management Comments

• The sale of shares is mandated by the Issuer's election under its equity incentive plans to require the Reporting Person to fund this tax withholding obligation by completing a 'sell to cover' transaction with a brokerage firm designated by the Issuer.
• This sale does not represent a discretionary trade by the Reporting Person.

Industry Context

Sales of shares to cover tax obligations after vesting of restricted stock units are a common practice among corporate executives. The vesting of PSUs tied to clinical/regulatory milestones suggests progress in the company's drug development programs.

Comparison to Industry Standards

• Executive compensation packages often include performance-based equity awards like PSUs, aligning management incentives with company goals.
• The 'sell to cover' practice for tax obligations is a standard mechanism used by many companies to simplify the tax process for employees receiving equity compensation.
• Comparing Travere Therapeutics' executive compensation structure and PSU vesting criteria to those of similar-sized biotech companies would provide further context.

Stakeholder Impact

• Shareholders may view the PSU vesting as a positive sign of the company's progress.
• The sale of shares to cover tax obligations has a minimal impact on the overall market.

Key Dates

Keywords

Travere Therapeutics, Jula Inrig, PSU, FILSPARI, sNDA, FSGS, Stock Sale, Vesting, Chief Medical Officer, TVTX